

# Rekha Chaudhuri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1440883/publications.pdf>

Version: 2024-02-01

40  
papers

2,481  
citations

361413  
20  
h-index

289244  
40  
g-index

40  
all docs

40  
docs citations

40  
times ranked

2725  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Cigarette Smoking Impairs the Therapeutic Response to Oral Corticosteroids in Chronic Asthma. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 1308-1311.   | 5.6  | 421       |
| 2  | Effects of Smoking Cessation on Lung Function and Airway Inflammation in Smokers with Asthma. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 127-133.   | 5.6  | 271       |
| 3  | Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax, 2016, 71, 339-346.   | 5.6  | 257       |
| 4  | The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax, 2015, 70, 376-378.   | 5.6  | 152       |
| 5  | Remotely Monitored Therapy and Nitric Oxide Suppression Identifies Nonadherence in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 454-464.   | 5.6  | 115       |
| 6  | Obesity-Associated Severe Asthma Represents a Distinct Clinical Phenotype. Chest, 2013, 143, 406-414.   | 0.8  | 109       |
| 7  | Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. Lancet Respiratory Medicine, the, 2018, 6, 499-510. | 10.7 | 104       |
| 8  | Dedicated Severe Asthma Services Improve Health-care Use and Quality of Life. Chest, 2015, 148, 870-876.  | 0.8  | 100       |
| 9  | Statistical Cluster Analysis of the British Thoracic Society Severe Refractory Asthma Registry: Clinical Outcomes and Phenotype Stability. PLoS ONE, 2014, 9, e102987.  | 2.5  | 94        |
| 10 | Sputum matrix metalloproteinase-12 in patients with chronic obstructive pulmonary disease and asthma: Relationship to disease severity. Journal of Allergy and Clinical Immunology, 2012, 129, 655-663.e8.  | 2.9  | 90        |
| 11 | Composite type-2 biomarker strategy versus a symptomâ€‘risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respiratory Medicine, the, 2021, 9, 57-68.                             | 10.7 | 88        |
| 12 | Effect of inhaled corticosteroids on symptom severity and sputum mediator levels in chronic persistent cough. Journal of Allergy and Clinical Immunology, 2004, 113, 1063-1070.   | 2.9  | 77        |
| 13 | Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD. JAMA - Journal of the American Medical Association, 2018, 320, 1548.   | 7.4  | 67        |
| 14 | Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials. Lancet Respiratory Medicine, the, 2021, 9, 457-466.  | 10.7 | 63        |
| 15 | Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). BMJ Open, 2016, 6, e011857.  | 1.9  | 61        |
| 16 | The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. Lancet Respiratory Medicine, the, 2021, 9, 1174-1184.  | 10.7 | 49        |
| 17 | <i>In vitro</i> , <i>in silico</i> and <i>in vivo</i> study challenges the impact of bronchial thermoplasty on acute airway smooth muscle mass loss. European Respiratory Journal, 2018, 51, 1701680.   | 6.7  | 42        |
| 18 | Fractional Exhaled Nitric Oxide Nonsuppression Identifies Corticosteroid-Resistant Type 2 Signaling in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 731-734.   | 5.6  | 40        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Atorvastatin in combination with inhaled beclometasone modulates inflammatory sputum mediators in smokers with asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 31, 1-8.  | 2.6 | 29        |
| 20 | Effectiveness of bronchial thermoplasty in severe asthma in "real life" patients compared with those recruited to clinical trials in the same centre. <i>Therapeutic Advances in Respiratory Disease</i> , 2015, 9, 267-271.            | 2.6 | 28        |
| 21 | Details of development of the resource for adults with asthma in the RAISIN (randomized trial of an) Tj ETQq1 1 0.784314 rgBT /Over 2015, 15, 57.   | 3.0 | 21        |
| 22 | Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 267.       | 1.6 | 20        |
| 23 | Insights into frequent asthma exacerbations from a primary care perspective and the implications of UK National Review of Asthma Deaths recommendations. <i>Npj Primary Care Respiratory Medicine</i> , 2018, 28, 35.                   | 2.6 | 20        |
| 24 | Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study. <i>Thorax</i> , 2019, 74, 806-809.                             | 5.6 | 18        |
| 25 | Sputum matrix metalloproteinase-9 is associated with the degree of emphysema on computed tomography in COPD. <i>Translational Respiratory Medicine</i> , 2013, 1, 11.   | 3.8 | 16        |
| 26 | 5-Year Survival after Endobronchial Coil Implantation: Secondary Analysis of the First Randomised Controlled Trial, RESET. <i>Respiration</i> , 2020, 99, 154-162.  | 2.6 | 15        |
| 27 | The impact of the first COVID-19 surge on severe asthma patients in the UK. Which is worse: the virus or the lockdown?. <i>ERJ Open Research</i> , 2021, 7, 00768-2020.   | 2.6 | 14        |
| 28 | Ethnic Differences in Severe Asthma Clinical Care and Outcomes: An Analysis of United Kingdom Primary and Specialist Care. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 495-505.e2.                       | 3.8 | 14        |
| 29 | Exacerbation Profile and Risk Factors in a Type-2"Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 545-553. | 5.6 | 14        |
| 30 | Factors Associated with Frequent Exacerbations in the UK Severe Asthma Registry. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2691-2701.e1.  | 3.8 | 13        |
| 31 | Effects of older age and age of asthma onset on clinical and inflammatory variables in severe refractory asthma. <i>Respiratory Medicine</i> , 2016, 118, 46-52.  | 2.9 | 12        |
| 32 | Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker"high and "low severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2974-2986.                | 5.7 | 11        |
| 33 | Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma. <i>European Respiratory Journal</i> , 2022, 59, 2100768.  | 6.7 | 8         |
| 34 | Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-146.                    | 2.8 | 7         |
| 35 | Biologics in severe asthma: Which one, When and Where?. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1225-1228.   | 2.9 | 5         |
| 36 | Utility of fractional exhaled nitric oxide suppression as a prediction tool for progression to biologic therapy. <i>ERJ Open Research</i> , 2021, 7, 00273-2021.  | 2.6 | 5         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Recommendations following a modified UK-Delphi consensus study on best practice for referral and management of severe asthma. <i>BMJ Open Respiratory Research</i> , 2021, 8, e001057.                           | 3.0 | 4         |
| 38 | The effect of the COVID-19 pandemic on severe asthma care in Europe - will care change for good?. <i>ERJ Open Research</i> , 2022, 8, 00065-2022.  | 2.6 | 3         |
| 39 | Using prednisolone and cortisol assays to assess adherence in oral corticosteroid dependant asthma: An analysis of test-retest repeatability. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 64, 101951. | 2.6 | 2         |
| 40 | Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). <i>Trials</i> , 2022, 23, 307.     | 1.6 | 2         |